skip to main content

Main Site Navigation

Top of main content

Clinical Trials Details

COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

Location: Carle - Heart & Vascular Institute
Body site or condition: Cardiovascular
Department: Cardiology

18HVI1902 - COBRA-REDUCE

The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 3 or 6-month DAPT.

Apply Now